Loading clinical trials...

10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals | Clinical Trials | Clareo Health

UNKNOWNNA

10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals

Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-episode Non-affective Psychosis Individuals: a 10-year Follow-up

NCT03090490•Fundación Marques de Valdecilla

View on ClinicalTrials.gov

Summary

This open-label, non-randomized, prospective study will evaluate the risk of symptoms recurrence during the ten years after antipsychotic discontinuation in a sample of functionally recovered first-episode patients with schizophrenia spectrum disorder.

Eligibility

Age

15 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals included in the First Episode Psychosis Clinical Program (PAFIP) at the University Hospital Marqués de Valdecilla (Santander, Spain).
•A minimum of 18 months on antipsychotic treatment.
•Meeting clinical remission criteria for at least the 12 months prior to inclusion.
•Meeting the functional recovery criteria for at least the 6 months prior to inclusion.
•Stabilized at the lowest effective doses for at least the 3 months prior to inclusion.

Exclusion Criteria

•Meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for drug dependence.
•Meeting DSM-IV criteria for mental retardation.
•Having a history of neurological disease or head injury.

Locations (1)

University Hospital Marques de Valdecilla

Santander, Cantabria, Spain

Key Dates

Start Date

September 1, 2014

Primary Completion Date

December 1, 2017

Completion Date

December 1, 2020

Last Updated

January 14, 2020

Enrollment

ESTIMATED participants

Conditions

SchizophreniaSchizophrenia RelapseSchizophrenia Spectrum and Other Psychotic Disorders

Interventions

Antipsychotic treatment discontinuation

OTHER

Maintenance treatment discontinuation

OTHER

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 14, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia